ClinicalTrials.gg
CompletedNCT00925769Updated Aug 7, 2015Results posted

ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer

A Phase 1 interventional study of bevacizumab [Avastin] and capecitabine [Xeloda] in Pancreatic Cancer, sponsored by Hoffmann-La Roche. Completed at 2 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-07.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing bevacizumab in Pancreatic Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. Bevacizumab · Pancreatic Neoplasms.

Enrollment
21st of 36
32 · median 43
Started
2009
the only one that year
Phase 1
8 of 36
none open now
Registered
27th of 36
by date
Lead sponsor
2 of 36
Hoffmann-La Roche

Among the 36 studies testing bevacizumab in Pancreatic Neoplasms, this one is the 21st largest by enrollment, is the only one that started in 2009, is one of 8 in phase 1, and was the 27th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

1 of the 36 studies testing bevacizumab in Pancreatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing bevacizumab in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This 2 part study will evaluate the safety and efficacy of a combination of Avastin, Tarceva and Xeloda (ATX) as second-line treatment in patients with locally advanced and/or metastatic pancreatic cancer. In the first part of the study, cohorts of patients will receive escalating doses of combination treatment to determine the maximum tolerated dose. The recommended dose will be used in the second part of the study to determine the efficacy of the ATX regime, in terms of its effect on disease progression. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • pancreatic cancer with locally advanced and/or disease (stage IV);
  • chemonaive for metastatic or locally advanced disease;
  • performance status of 0-2.

Exclusion criteria

Exclusion Criteria:

  • local (stage IA to IIB)and locally advanced (stage III) pancreatic cancer;
  • previous exposure to Avastin, Tarceva or Xeloda;
  • other primary tumor within the last 5 years prior to enrollment, except for adequately treated cancer in situ of cervix, or basal cell skin cancer;
  • current or recent chronic use of aspirin (>325 mg/day) or full therapeutic dose of anticoagulants or thrombolytic agents.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda] · Drug: erlotinib [Tarceva]

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Maximum Tolerated Dose (MTD) of Capecitabine

    MTD for each of the medications was defined as the lowest dose studied which resulted in dose limiting toxicity (DLT) in at least 33 percent (%) of participants of the same quality category. DLT was defined as any greater than or equal to (\>=) Grade (G) 3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to adverse events (AEs).

    Time frame: Up to Week 6 (Cycle 1-3)

  2. Part 1: MTD of Erlotinib

    MTD for each of the medications was defined as the lowest dose studied which resulted in DLT in at least 33% of participants of the same quality category. DLT was defined as \>= G3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to AEs.

    Time frame: Up to Week 6 (Cycle 1-3)

  3. Part 1: MTD of Bevacizumab

    MTD for each of the medications was defined as the lowest dose studied which resulted in DLT in at least 33% of participants of the same quality category. DLT was defined as \>= G3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to AEs.

    Time frame: Up to Week 6 (Cycle 1-3)

  4. Part 1: Preliminary Recommended Dose (PRD) of Capecitabine for Part 2

    Once the MTD was reached then the preceding lower dose level was used as PRD. MTD for each of the medications was defined as the lowest dose studied which resulted in dose limiting toxicity (DLT) in at least 33% of participants of the same quality category. DLT was defined as \>= G3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to AEs. If MTD was not defined for a drug treatment then the maximum planned dose of that particular drug was considered as PRD for Part 2.

    Time frame: Up to Week 6 (Cycle 1-3)

  5. Part 1: PRD of Erlotinib for Part 2

    Once the MTD was reached then the preceding lower dose level was used as PRD. MTD for each of the medications was defined as the lowest dose studied which resulted in DLT in at least 33% of participants of the same quality category. DLT was defined as \>= G3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to AEs. If MTD was not defined for a drug treatment then the maximum planned dose of that particular drug was considered as PRD for Part 2.

    Time frame: Up to Week 6 (Cycle 1-3)

  6. Part 1: PRD of Bevacizumab for Part 2

    Once the MTD was reached then the preceding lower dose level was used as PRD. MTD for each of the medications was defined as the lowest dose studied which resulted in DLT in at least 33% of participants of the same quality category. DLT was defined as \>= G3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to AEs. If MTD was not defined for a drug treatment then the maximum planned dose of that particular drug was considered as PRD for Part 2.

    Time frame: Up to Week 6 (Cycle 1-3)

Secondary outcomes

  1. Part 1: Maximum Serum Concentration (Cmax) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-Deoxy-5-Fluorocytidine [5'-DFCR] and 5'-Deoxy-5-Fluorouridine [5'-DFUR])

    Time frame: CAP: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 hours (h) of every 2-week cycle (until Week 259) ERL: 2, 3 4, 5, 6, 7, 8, 10, 24, 28, 48, 52, 72, 76, 96, 100, 120, 124, 144, 148, 168 and 172 h of every 2-week cycle (until Week 259)

  2. Part 1: Time to Reach Cmax (Tmax) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-DFCR and 5'-DFUR)

    Time frame: CAP: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 hours (h) of every 2-week cycle (until Week 259) ERL: 2, 3 4, 5, 6, 7, 8, 10, 24, 28, 48, 52, 72, 76, 96, 100, 120, 124, 144, 148, 168 and 172 h of every 2-week cycle (until Week 259)

  3. Part 1: Last Quantifiable Drug Concentration (Clast) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-DFCR and 5'-DFUR)

    Time frame: CAP: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 hours (h) of every 2-week cycle (until Week 259) ERL: 2, 3 4, 5, 6, 7, 8, 10, 24, 28, 48, 52, 72, 76, 96, 100, 120, 124, 144, 148, 168 and 172 h of every 2-week cycle (until Week 259)

  4. Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUClast) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-DFCR and 5'-DFUR)

    Time frame: CAP: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 hours (h) of every 2-week cycle (until Week 259) ERL: 2, 3 4, 5, 6, 7, 8, 10, 24, 28, 48, 52, 72, 76, 96, 100, 120, 124, 144, 148, 168 and 172 h of every 2-week cycle (until Week 259)

  5. Part 2: Percentage of Participants Free From Disease Progression

    As per Response Evaluation Criteria In Solid Tumors (RECIST) version (v) 1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of 1 or more new lesions (target and non-target lesions) or the unequivocal progression of existing non-target lesions.

    Time frame: Month 6

  6. Part 2: Percentage of Participants With Disease Control

    A participant was defined as having controlled disease if they sustained a Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) during the assessment. As per RECIST v1.1, CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level; PR is defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the screening sum longest diameter; SD for target lesions is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started and SD for non-target lesions defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

    Time frame: From baseline thereafter, every 6 weeks (±7 days), then 1 week after last dose (follow-up), thereafter every 6 weeks (±7 days) until disease progression (up to Week 259)

  7. Part 2: Percentage of Participants With Clinical Benefit Response

    Clinical benefit response was defined as a composite of pain control, Karnofsky performance status (KPS), and weight. The KPS allows participants to be classified as per their functional impairment (abnormal function). It was recorded on an 11-point scale; 0= "dead" to 100= "Normal, no complaints, no evidence of disease" and sub-divided to 3 categories; 0 to 40 = "Unable to care for self, requires institutional or hospital care or equivalent, disease may be rapidly progressing"; 50 to 70= "Unable to work, able to live at home and care for most personal needs, varying amount of assistance needed and 80 to 100= "Able to carry on normal activity; no special care is needed".

    Time frame: One week before start of study treatment and weekly until disease progression or death (Up to Week 259)

  8. Part 2: Overall Survival

    Survival was the interval of time from date of first dose of study medication to date of death at any time. Participants who had not died were censored at the date of last contact when they were known to be alive.

    Time frame: From baseline until death (Up to Week 259)

07

Results

Posted Aug 7, 2015
Limitations and caveats
Planned Part 2 of the study was not implemented and outcome measures related to Part 2 were not analyzed.

Participant flow

Participant flow — Overall Study
MilestoneERL+BEV+CAP Dose Level-1ERL+BEV+CAP Dose Level-2ERL+BEV+CAP Dose Level-3ERL+BEV+CAP Dose Level-4ERL+BEV+CAP Dose Level-5ERL+BEV+CAP Dose Level-6
Started666633
Completed000000
Not completed666633
Withdrew: Major toxicity101100
Withdrew: Disease progression453423
Withdrew: Death001000
Withdrew: Physician decision100000
Withdrew: Missing documentation010000
Withdrew: End of study visit not done001000
Withdrew: Participant is unable to swallow drug000100
Withdrew: Adverse event000010

Outcome measures

PrimaryPart 1: Maximum Tolerated Dose (MTD) of Capecitabine

MTD for each of the medications was defined as the lowest dose studied which resulted in dose limiting toxicity (DLT) in at least 33 percent (%) of participants of the same quality category. DLT was defined as any greater than or equal to (\>=) Grade (G) 3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to adverse events (AEs).

Time frame:
Up to Week 6 (Cycle 1-3)
Reported as:
Number · mg/m^2 BID
Part 1: Maximum Tolerated Dose (MTD) of Capecitabine
mg/m^2 BIDTriple Combination (Bevacizumab/Erlotinib/Capecitabine)
Part 1: Maximum Tolerated Dose (MTD) of Capecitabine900
PrimaryPart 1: MTD of Erlotinib

MTD for each of the medications was defined as the lowest dose studied which resulted in DLT in at least 33% of participants of the same quality category. DLT was defined as \>= G3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to AEs.

Time frame:
Up to Week 6 (Cycle 1-3)
Reported as:
Number · mg/day
Part 1: MTD of Erlotinib
mg/dayTriple Combination (Bevacizumab/Erlotinib/Capecitabine)
Part 1: MTD of ErlotinibNA
SecondaryPart 1: Maximum Serum Concentration (Cmax) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-Deoxy-5-Fluorocytidine [5'-DFCR] and 5'-Deoxy-5-Fluorouridine [5'-DFUR])
Time frame:
CAP: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 hours (h) of every 2-week cycle (until Week 259) ERL: 2, 3 4, 5, 6, 7, 8, 10, 24, 28, 48, 52, 72, 76, 96, 100, 120, 124, 144, 148, 168 and 172 h of every 2-week cycle (until Week 259)
Reported as:
Mean · micrograms per milliliter (µg/mL)
Part 1: Maximum Serum Concentration (Cmax) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-Deoxy-5-Fluorocytidine [5'-DFCR] and 5'-Deoxy-5-Fluorouridine [5'-DFUR])
micrograms per milliliter (µg/mL)ERL+BEV+CAP Dose Level-1ERL+BEV+CAP Dose Level-2ERL+BEV+CAP Dose Level-3ERL+BEV+CAP Dose Level-4ERL+BEV+CAP Dose Level-5ERL+BEV+CAP Dose Level-6
Erlotinib (n=6,6,6,6,3,3)1.50 ± 1.210.95 ± 0.580.68 ± 0.340.93 ± 0.630.58 ± 0.151.69 ± 0.67
OSI-420 (n=6,6,6,6,3,3)0.09 ± 0.070.05 ± 0.030.04 ± 0.020.06 ± 0.040.03 ± 0.010.10 ± 0.02
Capecitabine (n=6,6,6,6,3,3)1.69 ± 1.221.13 ± 0.614.89 ± 4.235.48 ± 4.519.47 ± 5.199.9 ± 5.01
5'-DFCR (n=5,5,6,6,3,3)3.5 ± 3.024.28 ± 1.6111.46 ± 5.326.26 ± 2.055.44 ± 2.434.15 ± 1.24
5'-DFUR (n=4,5,6,6,3,3)7.9 ± 4.417.3 ± 2.746.17 ± 2.637.24 ± 3.353.28 ± 0.725.1 ± 2.35
PrimaryPart 1: MTD of Bevacizumab

MTD for each of the medications was defined as the lowest dose studied which resulted in DLT in at least 33% of participants of the same quality category. DLT was defined as \>= G3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to AEs.

Time frame:
Up to Week 6 (Cycle 1-3)
Reported as:
Number · mg/kg once every 2 weeks (Q2W)
Part 1: MTD of Bevacizumab
mg/kg once every 2 weeks (Q2W)Triple Combination (Bevacizumab/Erlotinib/Capecitabine)
Part 1: MTD of BevacizumabNA
PrimaryPart 1: Preliminary Recommended Dose (PRD) of Capecitabine for Part 2

Once the MTD was reached then the preceding lower dose level was used as PRD. MTD for each of the medications was defined as the lowest dose studied which resulted in dose limiting toxicity (DLT) in at least 33% of participants of the same quality category. DLT was defined as \>= G3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to AEs. If MTD was not defined for a drug treatment then the maximum planned dose of that particular drug was considered as PRD for Part 2.

Time frame:
Up to Week 6 (Cycle 1-3)
Reported as:
Number · mg/m^2 BID
Part 1: Preliminary Recommended Dose (PRD) of Capecitabine for Part 2
mg/m^2 BIDTriple Combination (Bevacizumab/Erlotinib/Capecitabine)
Part 1: Preliminary Recommended Dose (PRD) of Capecitabine for Part 2800
SecondaryPart 1: Time to Reach Cmax (Tmax) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-DFCR and 5'-DFUR)
Time frame:
CAP: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 hours (h) of every 2-week cycle (until Week 259) ERL: 2, 3 4, 5, 6, 7, 8, 10, 24, 28, 48, 52, 72, 76, 96, 100, 120, 124, 144, 148, 168 and 172 h of every 2-week cycle (until Week 259)
Reported as:
Median · hours (h)
Part 1: Time to Reach Cmax (Tmax) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-DFCR and 5'-DFUR)
hours (h)ERL+BEV+CAP Dose Level-1ERL+BEV+CAP Dose Level-2ERL+BEV+CAP Dose Level-3ERL+BEV+CAP Dose Level-4ERL+BEV+CAP Dose Level-5ERL+BEV+CAP Dose Level-6
Erlotinib (n=6,6,6,6,3,3)2.50 (1.00 to 8.00)2.00 (2.00 to 8.00)2.00 (1.00 to 6.00)3.00 (2.00 to 8.00)5.00 (4.00 to 6.00)2.00 (2.00 to 3.00)
OSI-420 (n=6,6,6,6,3,3)3.00 (1.00 to 8.00)2.00 (2.00 to 24.00)2.00 (1.00 to 8.00)7.00 (2.00 to 24.00)6.00 (6.00 to 6.00)4.00 (2.00 to 4.00)
Capecitabine (n=6,6,6,6,3,3)0.5 (0.5 to 5)1 (0.5 to 3)1.5 (0.5 to 3)0.75 (0.5 to 2)1 (0.5 to 2)0.5 (0.5 to 1)
5'-DFCR (n=5,5,6,6,3,3)0.5 (0.5 to 2.5)1 (1 to 1.5)1.5 (0.5 to 2.5)1 (0.5 to 2)1 (0.5 to 2.5)1.5 (0.5 to 2.5)
5'-DFUR (n=4,5,6,6,3,3)1 (1 to 2.5)1.5 (1 to 2)1.5 (0.5 to 2.5)1.5 (0.5 to 2)1 (0.5 to 2.5)1.5 (1 to 2)
SecondaryPart 1: Last Quantifiable Drug Concentration (Clast) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-DFCR and 5'-DFUR)
Time frame:
CAP: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 hours (h) of every 2-week cycle (until Week 259) ERL: 2, 3 4, 5, 6, 7, 8, 10, 24, 28, 48, 52, 72, 76, 96, 100, 120, 124, 144, 148, 168 and 172 h of every 2-week cycle (until Week 259)
Reported as:
Mean · µg/mL
Part 1: Last Quantifiable Drug Concentration (Clast) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-DFCR and 5'-DFUR)
µg/mLERL+BEV+CAP Dose Level-1ERL+BEV+CAP Dose Level-2ERL+BEV+CAP Dose Level-3ERL+BEV+CAP Dose Level-4ERL+BEV+CAP Dose Level-5ERL+BEV+CAP Dose Level-6
Erlotinib (n=6,6,6,6,3,3)0.37 ± 0.360.31 ± 0.190.23 ± 0.110.39 ± 0.390.23 ± 0.020.52 ± 0.19
OSI-420 (n=6,6,6,6,3,3)0.04 ± 0.060.02 ± 0.010.01 ± 0.010.04 ± 0.040.01 ± 0.000.04 ± 0.01
Capecitabine (n=6,6,6,6,3,3)0.05 ± 0.060.2 ± 0.20.17 ± 0.150.06 ± 0.030.29 ± 0.260.17 ± 0.1
5'-DFCR (n=5,5,6,6,3,3)0.23 ± 0.230.08 ± 0.040.64 ± 0.60.75 ± 0.890.99 ± 1.220.3 ± 0.1
5'-DFUR (n=4,5,6,6,3,3)2.54 ± 0.141.03 ± 1.050.77 ± 0.920.58 ± 0.490.14 ± 0.080.14 ± 0.05
SecondaryPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUClast) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-DFCR and 5'-DFUR)
Time frame:
CAP: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 hours (h) of every 2-week cycle (until Week 259) ERL: 2, 3 4, 5, 6, 7, 8, 10, 24, 28, 48, 52, 72, 76, 96, 100, 120, 124, 144, 148, 168 and 172 h of every 2-week cycle (until Week 259)
Reported as:
Mean · h*µg/mL
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUClast) of Erlotinib and Its Metabolite OSI-420 (CP373420), Capecitabine and Its Metabolites (5'-DFCR and 5'-DFUR)
h*µg/mLERL+BEV+CAP Dose Level-1ERL+BEV+CAP Dose Level-2ERL+BEV+CAP Dose Level-3ERL+BEV+CAP Dose Level-4ERL+BEV+CAP Dose Level-5ERL+BEV+CAP Dose Level-6
Erlotinib (n=6,6,6,6,3,3)15.81 ± 12.9111.06 ± 5.419.15 ± 4.3913.07 ± 11.038.54 ± 1.9619.88 ± 4.75
OSI-420 (n=6,6,6,6,3,3)1.15 ± 1.210.48 ± 0.350.41 ± 0.180.99 ± 0.730.36 ± 0.031.42 ± 0.17
Capecitabine (n=6,6,6,6,3,3)1.43 ± 1.021.63 ± 1.015.88 ± 6.285.28 ± 3.2513.63 ± 8.639.74 ± 3.02
5'-DFCR (n=5,5,6,6,3,3)3.97 ± 2.657.01 ± 1.8920.27 ± 11.539.35 ± 3.2612.63 ± 9.898.06 ± 2.14
5'-DFUR (n=4,5,6,6,3,3)15.42 ± 9.4513.58 ± 7.849.76 ± 4.6010.86 ± 4.965.17 ± 0.898.53 ± 1.87
SecondaryPart 2: Percentage of Participants Free From Disease Progression

As per Response Evaluation Criteria In Solid Tumors (RECIST) version (v) 1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of 1 or more new lesions (target and non-target lesions) or the unequivocal progression of existing non-target lesions.

Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryPart 2: Percentage of Participants With Disease Control

A participant was defined as having controlled disease if they sustained a Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) during the assessment. As per RECIST v1.1, CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level; PR is defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the screening sum longest diameter; SD for target lesions is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started and SD for non-target lesions defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

Time frame:
From baseline thereafter, every 6 weeks (±7 days), then 1 week after last dose (follow-up), thereafter every 6 weeks (±7 days) until disease progression (up to Week 259)

No measurements were reported for this outcome.

SecondaryPart 2: Percentage of Participants With Clinical Benefit Response

Clinical benefit response was defined as a composite of pain control, Karnofsky performance status (KPS), and weight. The KPS allows participants to be classified as per their functional impairment (abnormal function). It was recorded on an 11-point scale; 0= "dead" to 100= "Normal, no complaints, no evidence of disease" and sub-divided to 3 categories; 0 to 40 = "Unable to care for self, requires institutional or hospital care or equivalent, disease may be rapidly progressing"; 50 to 70= "Unable to work, able to live at home and care for most personal needs, varying amount of assistance needed and 80 to 100= "Able to carry on normal activity; no special care is needed".

Time frame:
One week before start of study treatment and weekly until disease progression or death (Up to Week 259)

No measurements were reported for this outcome.

SecondaryPart 2: Overall Survival

Survival was the interval of time from date of first dose of study medication to date of death at any time. Participants who had not died were censored at the date of last contact when they were known to be alive.

Time frame:
From baseline until death (Up to Week 259)

No measurements were reported for this outcome.

PrimaryPart 1: PRD of Erlotinib for Part 2

Once the MTD was reached then the preceding lower dose level was used as PRD. MTD for each of the medications was defined as the lowest dose studied which resulted in DLT in at least 33% of participants of the same quality category. DLT was defined as \>= G3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to AEs. If MTD was not defined for a drug treatment then the maximum planned dose of that particular drug was considered as PRD for Part 2.

Time frame:
Up to Week 6 (Cycle 1-3)
Reported as:
Number · mg/day
Part 1: PRD of Erlotinib for Part 2
mg/dayTriple Combination (Bevacizumab/Erlotinib/Capecitabine)
Part 1: PRD of Erlotinib for Part 2150
PrimaryPart 1: PRD of Bevacizumab for Part 2

Once the MTD was reached then the preceding lower dose level was used as PRD. MTD for each of the medications was defined as the lowest dose studied which resulted in DLT in at least 33% of participants of the same quality category. DLT was defined as \>= G3 or G4 toxicity; \>= G3 non-hematological toxicities directly related to study treatment (other than untreated nausea/vomiting, alopecia, G3/G4 bilirubinemia for less than 7 days due to edema of the ductus choledochus and anemia); G4 thrombocytopenia, neutropenia lasting \>= 7 days or G3 thrombocytopenia with complications, requiring transfusions, febrile neutropenia; stopping of oral CAP and/or ERL intake for \>= 7 days, and/or cancellation of one or more BEV infusion(s) due to AEs. If MTD was not defined for a drug treatment then the maximum planned dose of that particular drug was considered as PRD for Part 2.

Time frame:
Up to Week 6 (Cycle 1-3)
Reported as:
Number · mg/kg Q2W
Part 1: PRD of Bevacizumab for Part 2
mg/kg Q2WTriple Combination (Bevacizumab/Erlotinib/Capecitabine)
Part 1: PRD of Bevacizumab for Part 210

Adverse events

Collected over From screening up to 30 days after the last chemotherapy treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ERL+BEV+CAP Dose Level-1—3/6 (50%)6/6 (100%)
ERL+BEV+CAP Dose Level-2—2/6 (33.3%)5/6 (83.3%)
ERL+BEV+CAP Dose Level-3—4/6 (66.7%)6/6 (100%)
ERL+BEV+CAP Dose Level-4—5/6 (83.3%)6/6 (100%)
ERL+BEV+CAP Dose Level-5—3/3 (100%)3/3 (100%)
ERL+BEV+CAP Dose Level-6—3/3 (100%)3/3 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventERL+BEV+CAP Dose Level-1ERL+BEV+CAP Dose Level-2ERL+BEV+CAP Dose Level-3ERL+BEV+CAP Dose Level-4ERL+BEV+CAP Dose Level-5ERL+BEV+CAP Dose Level-6
AnemiaBlood and lymphatic system disorders0/60/60/60/60/31/3
Abdominal painGastrointestinal disorders0/60/60/60/60/31/3
Gastrointestinal haemorrhageGastrointestinal disorders0/60/60/60/61/30/3
VomitingGastrointestinal disorders1/60/60/60/61/30/3
InfectionInfections and infestations0/60/60/60/61/30/3
Skeletal painMusculoskeletal and connective tissue disorders0/60/60/60/61/30/3
AphasiaNervous system disorders0/60/60/60/60/31/3
VertigoNervous system disorders0/60/60/60/61/31/3
DyspnoeaRespiratory, thoracic and mediastinal disorders0/60/61/62/60/30/3
PneumoniaRespiratory, thoracic and mediastinal disorders0/60/60/60/61/30/3
Most frequent other events
Showing 10 of 92
Most frequent other events
EventERL+BEV+CAP Dose Level-1ERL+BEV+CAP Dose Level-2ERL+BEV+CAP Dose Level-3ERL+BEV+CAP Dose Level-4ERL+BEV+CAP Dose Level-5ERL+BEV+CAP Dose Level-6
FatigueGeneral disorders6/63/63/63/62/32/3
Palmar-plantar erythrodyesthesiaSkin and subcutaneous tissue disorders2/65/63/63/61/30/3
Rash erythematousSkin and subcutaneous tissue disorders3/65/64/64/62/32/3
Abdominal painGastrointestinal disorders3/64/63/62/61/30/3
DiarrhoeaGastrointestinal disorders2/64/64/64/60/32/3
NauseaGastrointestinal disorders4/62/64/64/62/32/3
VomitingGastrointestinal disorders1/63/64/64/61/31/3
Appetite lossMetabolism and nutrition disorders4/61/62/64/60/31/3
VertigoNervous system disorders1/61/61/61/62/31/3
RhinitisRespiratory, thoracic and mediastinal disorders1/60/61/62/60/32/3

Baseline characteristics

Per-protocol population: All participants who received at least 1 evaluation period of 3 cycles of the complete study regimen (of all 3 drugs) at the recommended dose unless withdrawn from therapy earlier because of toxicity.

Age, Continuous
Age, Continuous(years)Triple Combination (Bevacizumab/Erlotinib/Capecitabine)
Mean63.9 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Triple Combination (Bevacizumab/Erlotinib/Capecitabine)
Female15
Male15
08

Study locations

2 sites
  • Vienna, 1100, Austria
  • Wien, 1130, Austria
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2009
First posted
Jun 22, 2009
Start
Jan 2009
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Aug 7, 2015
Last update
Aug 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00925769
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 22, 2009
Start date
Jan 2009
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Aug 7, 2015
Last update
Aug 7, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Capecitabine · Erlotinib

Start the discussion